@prefix this: . @prefix sub: . @prefix np: . @prefix rdf: . @prefix xsd: . @prefix rdfs: . @prefix ns2: . @prefix ns1: . @prefix prov: . @prefix ns3: . @prefix npx: . sub:Head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:pubInfo; a np:Nanopublication . } sub:assertion { ns1:reduce . } sub:provenance { sub:assertion prov:generatedAtTime "2021-12-16T19:44:19.297900"^^xsd:dateTime; prov:wasGeneratedBy "S&T TWOC project version 2" . sub:version prov:value "2"^^xsd:integer . rdf:OBJECT rdfs:label "the incidence of PONV ( 3.05 % , 22/721 )" . rdf:OBJECT-POSITION rdfs:label "16"^^xsd:integer . rdf:PREDICATE rdfs:label "reduced" . rdf:PREDICATE-POSITION rdfs:label "[67]" . rdf:SUBJECT rdfs:label "Results dexamethasone and 5-HT3 antagonist combination" . rdf:SUBJECT-POSITION rdfs:label "32"^^xsd:integer . rdfs:ABSTRACT-UID ns2:50 "d2wau7rl" . rdfs:SENTENCE rdfs:label "Results dexamethasone and 5-HT3 antagonist combination effectively reduced the incidence of PONV (3.05%, 22/721), and the patients who experienced PONV had statistically prolonged phase II recovery time as compared those who did not (P) = 0.006)." . rdfs:TRIPLE-UID ns3:d2wau7rl-TRIPLE-ABSTRACT-5 "d2wau7rl-TRIPLE-ABSTRACT-5" . rdfs:label "antagonist" . rdfs:label "ponv" . } sub:pubInfo { sub:assertion prov:wasDerivedFrom . sub:sig npx:hasAlgorithm "RSA"; npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCSLeezU8JYlBsrgXOGXX4fxOq4oydsMzMK1CN0Rez2OEd2IYk18R4DetcZXwGhN3Pil7qcgNkiGvTirJXIo8zHl7jVehs19EdYtrttCKEaXRzWIr4LuCrfGedkvonEMWqR8e1GdQsLgEEyM50BD6Qw+srQt9ozcqf/9wG2MAMX9QIDAQAB"; npx:hasSignature "IC0bvAVXtUmAnAX49MOQwsZHxet/iZ0gvb7M3n/vYzmX2943438mDwuOhVv6fnqO4y+jMKMEbyBXP6fvUei2zW3OVf2x395hbCr8ttVcdprdkzA156slbSjPz4W/i4TLI582EUdJebB9ug8JtIlI/wtz+cr0u70yuVC67Lf0obg="; npx:hasSignatureTarget this: . this: prov:generatedAtTime "2021-12-16T19:44:19.297900"^^xsd:dateTime; prov:wasAttributedTo . }